The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 (DTRM-12), and combination products, with everolimus and pomalidomide, in pts with CLL or other B-cell lymphomas.
 
Jennifer Gill
No Relationships to Disclose
 
Wei He
Employment - DTRM
Leadership - DTRM
Stock and Other Ownership Interests - DTRM
 
Stephen J. Schuster
Consulting or Advisory Role - Celgene; Gilead Sciences; Nordic Nanovector; Novartis; Pharmacyclics
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Danielle M. Brander
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences; Pharmacyclics; Teva
 
Elizabeth Chatburn
No Relationships to Disclose
 
Kaitlin Kennard
No Relationships to Disclose
 
Barry Douglas Anderson
No Relationships to Disclose
 
Sunita Nasta
Research Funding - Millennium
 
Daniel Jeffrey Landsburg
No Relationships to Disclose
 
David L. Porter
Employment - Genentech/Roche (I)
Stock and Other Ownership Interests - Genentech/Roche (I)
Honoraria - Incyte
Consulting or Advisory Role - Novartis
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Patent/royalty rights
Travel, Accommodations, Expenses - Immunovative Therapies
 
Ellen Napier
No Relationships to Disclose
 
Tanya Latorre
No Relationships to Disclose
 
Jakub Svoboda
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Pharmacyclics; Seagen
Travel, Accommodations, Expenses - Merck
 
Victoria Addis
No Relationships to Disclose
 
Anthony R. Mato
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; Regeneron
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); DTRM (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst); Regeneron (Inst); TG Therapeutics (Inst)